ERBB2 and breast carcinoma: The approved HER2 small molecule inhibitors have significantly improved the prognosis of breast cancer patients with drug resistance and distant metastasis by targeting the key nodes of the related signaling pathway, which are categorized in Table 2 together with the drugs in clinical trials (Figure 4).